Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients

Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are orally active first-in-class new generation drugs for renal anemia. This extensive meta-analysis of randomized controlled trials (RCTs) was designed to provide clear information on the efficacy and safety of HIF-PHIs on anemia in...

Full description

Bibliographic Details
Main Authors: Bin Wang, Qing Yin, Yu-Chen Han, Min Wu, Zuo-Lin Li, Yan Tu, Le-ting Zhou, Qing Wei, Hong Liu, Ri-Ning Tang, Jing-Yuan Cao, Lin-Li Lv, Bi-Cheng Liu
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Renal Failure
Subjects:
hif-phis
renal anemia
chronic kidney disease
meta-analysis
Online Access:http://dx.doi.org/10.1080/0886022X.2020.1811121

Internet

http://dx.doi.org/10.1080/0886022X.2020.1811121

Similar Items